NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDA
Post# of 66
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that it will participate in the virtual H.C. Wainwright BioConnect Conference taking place on Jan. 11-14, 2021. According to the update, AzurRx BioPharma president and CEO James Sapirstein will take part in virtual one-on-one meetings with registered investors and pharmaceutical companies. Sapirstein will be available to provide an overview of the company’s business and clinical development programs, as well as discuss anticipated 2021 milestones. Interested parties should visit https://nnw.fm/g3gtI to register for the event.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer